Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Down 57.4% in November

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCYGet Free Report) saw a significant drop in short interest in November. As of November 15th, there was short interest totalling 14,600 shares, a drop of 57.4% from the October 31st total of 34,300 shares. Based on an average trading volume of 254,600 shares, the days-to-cover ratio is currently 0.1 days.

Chugai Pharmaceutical Trading Up 1.7 %

OTCMKTS:CHGCY traded up $0.37 during trading hours on Friday, reaching $22.00. The company had a trading volume of 50,912 shares, compared to its average volume of 128,568. Chugai Pharmaceutical has a 1-year low of $14.52 and a 1-year high of $26.00. The business’s 50 day moving average price is $23.25 and its 200-day moving average price is $20.81.

About Chugai Pharmaceutical

(Get Free Report)

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

Recommended Stories

Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.